| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Tudor Pop
Omar Beirat
Rosalio Madrigal
Tudor Pop
| Share Statistics | KNSA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6,101.5 | $251.9 | 70% |
|
| Shares Out (Mil) | 83.4 | 50.8 | 59% |
|
| Institutional Ownership | 92.9% | 92.0% | 62% |
|
| Float (Mil) | 44.2 | 40.5 | 45% |
|
| Beta | 0.07 | 0.95 | 8% |
|
| Avg Daily Volume (000s) | 903 | 447 | 69% |
|
| Price Change (52-week) |
157.5% | 54.2% | 96% |
|
| Growth | KNSA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.0% | na |
|
| Net Income (5yr) | 18.8% | (9.8%) | 71% |
|
| EPS (5yr) | 18.0% | 16.3% | 64 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (17.3%) | (15.6%) | 40% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | $0.310 | $1.133 | $1.523 | |
| Month Ago EPS | $0.323 | $1.200 | $1.758 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $0.323 | $1.200 | $1.758 | |
| Year/Year Chg | 3.3% | 51.1% | 199.6% | |
| Financials | KNSA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $841 | $39 | 48% |
|
| Net Income (TTM) (Mil) | $81 | ($43) | 59% |
|
| EPS (TTM) | $1.058 | ($1.600) | 62% |
|
| Operating Cash Flow (TTM) (Mil) | $185 | ($30) | 58% |
|
| Net Cash Flow (TTM) (Mil) | ($16) | $3 | 28% |
|
| Long-Term Debt (Q1) (Mil) | $5 | $5 | 24% |
|
| Enterprise Value (Q1) (Mil) | $5,797 | $182 | 65% |
|
| Valuation | KNSA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 9.32 | 2.60 | 89% |
|
| P/E | 79.0 | 18.6 | 91% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 4.4 | 0.9 | 85% |
|
| Ratios | KNSA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 54.5% | 63.8% | 66% |
|
| Net Margin | 9.6% | (64.7%) | 62% |
|
| ROA | 10.4% | (49.7%) | 88% |
|
| ROE | 14.0% | (55.4%) | 69% |
|
| Liabilities to Assets | 27.0% | 30.3% | 18% |
|
| F-Score | 8 | 3 | na |
|
Kiniksa Pharmaceuticals International, plc did not pass any screens on 7/30/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
